Unlocking the Potential of ALLO-316: Allogene Therapeutics’ Groundbreaking Data Presentation for Advanced Renal Cell Carcinoma Patients
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) —
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer’s (SITC) annual meeting.
The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients.
The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its ability to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
How will this affect me?
As a patient with advanced or metastatic CD70 positive RCC who has failed multiple standard RCC therapies, the potential approval and availability of ALLO-316 could offer a new treatment option that may improve outcomes and quality of life.
How will this affect the world?
The development and potential approval of ALLO-316 by Allogene Therapeutics could represent a significant advancement in the field of cancer treatment, particularly for patients with difficult-to-treat solid tumors like renal cell carcinoma. This innovative therapy has the potential to change the landscape of cancer care and improve survival rates for patients worldwide.
Conclusion
Allogene Therapeutics’ presentation of groundbreaking data from the TRAVERSE trial for ALLO-316 at major medical conferences signifies a key milestone in the development of innovative treatment options for advanced renal cell carcinoma patients. The potential approval of ALLO-316 could bring hope to those who have exhausted standard treatment options and provide a novel approach to addressing unmet medical needs in oncology.
